Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KH domain-containing protein overexpressed in cancer 1 (IGF2BP3)
- Target
- IGF2BP3
- Molecular classification
- RNA-binding protein, KH domain-containing protein
01
Overview
IGF2BP3 is an RNA-binding protein that regulates the stability, degradation, localization, and transport of target RNAs. It is overexpressed in various cancers and is considered a potential diagnostic marker. It contains two N-terminal RNA recognition motifs (RRMs) and four C-terminal K homology (KH) domains, which are critical for RNA binding.
- Other names
- IMP3KOCCT98KOC1VICKZ3insulin-like growth factor 2 mRNA binding protein 3
02
Mechanism of action
Small molecule inhibitors targeting related family members’ KH domains have shown promise preclinically—for example inhibiting KRAS-driven oncogenic signaling via disruption at specific KH domain interfaces.
03
Biological functions
Post-transcriptional regulationRNA stabilityTranslation regulationRNA localizationmRNA transportCell proliferationCell migrationCell invasion
04
Disease associations
CancerTumorigenesis
05
Safety considerations
Lack of approved drugs directly inhibiting IGF2BP3 clinically.Functions during development remain incompletely understood.
06
Biomarkers
Pancreatic cancerLung cancerBreast cancerHepatocellular carcinoma
Beyond the preview
Go deeper on KH domain-containing protein overexpressed in cancer 1 (IGF2BP3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KH domain-containing protein overexpressed in cancer 1 (IGF2BP3).